GHP Investment Advisors Inc. boosted its position in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 5.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,180 shares of the medical research company’s stock after purchasing an additional 545 shares during the period. GHP Investment Advisors Inc.’s holdings in Laboratory Corporation of America Holdings were worth $1,688,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LH. Swiss National Bank lifted its position in shares of Laboratory Corporation of America Holdings by 1.9% in the second quarter. Swiss National Bank now owns 460,275 shares of the medical research company’s stock worth $70,947,000 after buying an additional 8,500 shares during the last quarter. Sentry Investments Corp. lifted its position in shares of Laboratory Corporation of America Holdings by 29.6% in the second quarter. Sentry Investments Corp. now owns 924,900 shares of the medical research company’s stock worth $142,564,000 after buying an additional 211,180 shares during the last quarter. Allen Investment Management LLC lifted its position in shares of Laboratory Corporation of America Holdings by 13.7% in the second quarter. Allen Investment Management LLC now owns 732,798 shares of the medical research company’s stock worth $112,953,000 after buying an additional 88,564 shares during the last quarter. Taylor Asset Management Inc. lifted its position in shares of Laboratory Corporation of America Holdings by 1.8% in the second quarter. Taylor Asset Management Inc. now owns 51,600 shares of the medical research company’s stock worth $7,953,000 after buying an additional 900 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in shares of Laboratory Corporation of America Holdings by 2.3% in the second quarter. PNC Financial Services Group Inc. now owns 39,891 shares of the medical research company’s stock worth $6,150,000 after buying an additional 881 shares during the last quarter. 93.84% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have weighed in on LH. Zacks Investment Research raised Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Craig Hallum reiterated a “buy” rating and issued a $179.00 price objective (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Barclays PLC lifted their price objective on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Jefferies Group LLC reiterated a “hold” rating and issued a $170.00 price objective (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Wednesday, September 13th. Finally, ValuEngine upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research note on Wednesday, September 6th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $169.00.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.watchlistnews.com/ghp-investment-advisors-inc-grows-position-in-laboratory-corporation-of-america-holdings-lh/1690976.html.

Shares of Laboratory Corporation of America Holdings (NYSE:LH) traded down $1.70 on Thursday, reaching $150.09. The company had a trading volume of 279,869 shares, compared to its average volume of 707,266. Laboratory Corporation of America Holdings has a 1 year low of $119.51 and a 1 year high of $164.22. The company has a quick ratio of 1.75, a current ratio of 1.89 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $15,513.30, a price-to-earnings ratio of 16.39, a price-to-earnings-growth ratio of 1.62 and a beta of 0.87.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.08. Laboratory Corporation of America Holdings had a return on equity of 16.75% and a net margin of 7.40%. The firm had revenue of $2.60 billion for the quarter, compared to analyst estimates of $2.55 billion. During the same period in the previous year, the company posted $2.25 earnings per share. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. equities research analysts expect that Laboratory Corporation of America Holdings will post 9.52 earnings per share for the current fiscal year.

In related news, insider F Samuel Eberts III sold 31,500 shares of the business’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $155.22, for a total transaction of $4,889,430.00. Following the transaction, the insider now directly owns 31,894 shares in the company, valued at $4,950,586.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director R Sanders Williams sold 3,100 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $156.88, for a total value of $486,328.00. Following the transaction, the director now owns 10,073 shares in the company, valued at $1,580,252.24. The disclosure for this sale can be found here. Insiders have sold 212,971 shares of company stock worth $33,378,333 over the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.